Loading…
Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatini...
Saved in:
Published in: | Case reports in oncology 2020-05, Vol.13 (2), p.534-537 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c529t-f2728f69395d81658c0ea8aa10566dcf2ac2597b28c51561671dec1aec6553ae3 |
---|---|
cites | cdi_FETCH-LOGICAL-c529t-f2728f69395d81658c0ea8aa10566dcf2ac2597b28c51561671dec1aec6553ae3 |
container_end_page | 537 |
container_issue | 2 |
container_start_page | 534 |
container_title | Case reports in oncology |
container_volume | 13 |
creator | Sobash, Philip T. Guddati, Achuta K. Kota, Vamsi |
description | Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Most patients tend to respond to first-line treatment. Although there is a subset of patients who do not achieve complete molecular response with first line, newer options have proven beneficial. As we progress through therapies, there still remain some patients who do not adequately respond to current available therapies. The treatment options and guidelines become more difficult in such situations, not only with respect to cost but also patient quality of life and satisfaction. We discuss a 75-year-old white female with CML, who has had multiple therapies with hematological remission but has never achieved complete molecular remission, currently on bosutinib and tolerating it well. |
doi_str_mv | 10.1159/000506895 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_c9e85d8d727d45db9753bbe96a56efed</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_c9e85d8d727d45db9753bbe96a56efed</doaj_id><sourcerecordid>2447958188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-f2728f69395d81658c0ea8aa10566dcf2ac2597b28c51561671dec1aec6553ae3</originalsourceid><addsrcrecordid>eNptkU1r3DAQhk1paNKkh957EOTUg1tJ3tHHpVCWfgR2WQjNoScxlsZeb7zWVrZT9t_XqcPSQE8j5n14Bs1k2VvBPwgB9iPnHLgyFl5kF0IpmSvQ8PKf93n2uu93nCsLCl5l54UEYQD4RbZeY4c17akbWKwYMg35T8KUb9rAVhiO7HczbNktVQn9ENORLbcpdo1n6yO1saYujj1b0XhP-wavsrMK257ePNXL7O7rlx_L7_lq8-1m-XmVe5B2yCuppamULSwEIxQYzwkNouCgVPCVRC_B6lIaDwKUUFoE8gLJK4ACqbjMbmZviLhzh9TsMR1dxMb9bcRUO0xD41ty3pKZpgQtdVhAKK2GoizJKgRFFYXJ9Wl2HcZyT8FPm0jYPpM-T7pm6-r44LScVruASXD9JEjx10j94HZxTN30fycXC23BCGMm6v1M-RT7PlF1miC4e7yiO11xYt_N7D2mmtKJPMXX_42Xt5uZcIdQFX8AdTSiFA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2447958188</pqid></control><display><type>article</type><title>Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia</title><source>Open Access: PubMed Central</source><source>publisher website</source><creator>Sobash, Philip T. ; Guddati, Achuta K. ; Kota, Vamsi</creator><creatorcontrib>Sobash, Philip T. ; Guddati, Achuta K. ; Kota, Vamsi</creatorcontrib><description>Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Most patients tend to respond to first-line treatment. Although there is a subset of patients who do not achieve complete molecular response with first line, newer options have proven beneficial. As we progress through therapies, there still remain some patients who do not adequately respond to current available therapies. The treatment options and guidelines become more difficult in such situations, not only with respect to cost but also patient quality of life and satisfaction. We discuss a 75-year-old white female with CML, who has had multiple therapies with hematological remission but has never achieved complete molecular remission, currently on bosutinib and tolerating it well.</description><identifier>ISSN: 1662-6575</identifier><identifier>EISSN: 1662-6575</identifier><identifier>DOI: 10.1159/000506895</identifier><identifier>PMID: 32518550</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Biopsy ; Blood ; Bone marrow ; Case Report ; Case reports ; chronic myelogenous leukemia ; complete molecular remission ; Drug dosages ; Hematology ; Inhibitor drugs ; Kinases ; Leukemia ; Literature reviews ; major molecular response ; Mutation ; Patients ; refractory ; Remission (Medicine) ; Targeted cancer therapy ; tyrosine kinase inhibitors</subject><ispartof>Case reports in oncology, 2020-05, Vol.13 (2), p.534-537</ispartof><rights>2020 The Author(s). Published by S. Karger AG, Basel</rights><rights>Copyright © 2020 by S. Karger AG, Basel 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-f2728f69395d81658c0ea8aa10566dcf2ac2597b28c51561671dec1aec6553ae3</citedby><cites>FETCH-LOGICAL-c529t-f2728f69395d81658c0ea8aa10566dcf2ac2597b28c51561671dec1aec6553ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265745/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265745/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27635,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Sobash, Philip T.</creatorcontrib><creatorcontrib>Guddati, Achuta K.</creatorcontrib><creatorcontrib>Kota, Vamsi</creatorcontrib><title>Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia</title><title>Case reports in oncology</title><addtitle>Case Rep Oncol</addtitle><description>Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Most patients tend to respond to first-line treatment. Although there is a subset of patients who do not achieve complete molecular response with first line, newer options have proven beneficial. As we progress through therapies, there still remain some patients who do not adequately respond to current available therapies. The treatment options and guidelines become more difficult in such situations, not only with respect to cost but also patient quality of life and satisfaction. We discuss a 75-year-old white female with CML, who has had multiple therapies with hematological remission but has never achieved complete molecular remission, currently on bosutinib and tolerating it well.</description><subject>Biopsy</subject><subject>Blood</subject><subject>Bone marrow</subject><subject>Case Report</subject><subject>Case reports</subject><subject>chronic myelogenous leukemia</subject><subject>complete molecular remission</subject><subject>Drug dosages</subject><subject>Hematology</subject><subject>Inhibitor drugs</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Literature reviews</subject><subject>major molecular response</subject><subject>Mutation</subject><subject>Patients</subject><subject>refractory</subject><subject>Remission (Medicine)</subject><subject>Targeted cancer therapy</subject><subject>tyrosine kinase inhibitors</subject><issn>1662-6575</issn><issn>1662-6575</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>M--</sourceid><sourceid>DOA</sourceid><recordid>eNptkU1r3DAQhk1paNKkh957EOTUg1tJ3tHHpVCWfgR2WQjNoScxlsZeb7zWVrZT9t_XqcPSQE8j5n14Bs1k2VvBPwgB9iPnHLgyFl5kF0IpmSvQ8PKf93n2uu93nCsLCl5l54UEYQD4RbZeY4c17akbWKwYMg35T8KUb9rAVhiO7HczbNktVQn9ENORLbcpdo1n6yO1saYujj1b0XhP-wavsrMK257ePNXL7O7rlx_L7_lq8-1m-XmVe5B2yCuppamULSwEIxQYzwkNouCgVPCVRC_B6lIaDwKUUFoE8gLJK4ACqbjMbmZviLhzh9TsMR1dxMb9bcRUO0xD41ty3pKZpgQtdVhAKK2GoizJKgRFFYXJ9Wl2HcZyT8FPm0jYPpM-T7pm6-r44LScVruASXD9JEjx10j94HZxTN30fycXC23BCGMm6v1M-RT7PlF1miC4e7yiO11xYt_N7D2mmtKJPMXX_42Xt5uZcIdQFX8AdTSiFA</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Sobash, Philip T.</creator><creator>Guddati, Achuta K.</creator><creator>Kota, Vamsi</creator><general>S. Karger AG</general><general>Karger Publishers</general><scope>M--</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20200501</creationdate><title>Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia</title><author>Sobash, Philip T. ; Guddati, Achuta K. ; Kota, Vamsi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-f2728f69395d81658c0ea8aa10566dcf2ac2597b28c51561671dec1aec6553ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biopsy</topic><topic>Blood</topic><topic>Bone marrow</topic><topic>Case Report</topic><topic>Case reports</topic><topic>chronic myelogenous leukemia</topic><topic>complete molecular remission</topic><topic>Drug dosages</topic><topic>Hematology</topic><topic>Inhibitor drugs</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Literature reviews</topic><topic>major molecular response</topic><topic>Mutation</topic><topic>Patients</topic><topic>refractory</topic><topic>Remission (Medicine)</topic><topic>Targeted cancer therapy</topic><topic>tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sobash, Philip T.</creatorcontrib><creatorcontrib>Guddati, Achuta K.</creatorcontrib><creatorcontrib>Kota, Vamsi</creatorcontrib><collection>publisher website</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Open Access: DOAJ - Directory of Open Access Journals</collection><jtitle>Case reports in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sobash, Philip T.</au><au>Guddati, Achuta K.</au><au>Kota, Vamsi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia</atitle><jtitle>Case reports in oncology</jtitle><addtitle>Case Rep Oncol</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>13</volume><issue>2</issue><spage>534</spage><epage>537</epage><pages>534-537</pages><issn>1662-6575</issn><eissn>1662-6575</eissn><abstract>Chronic myelogenous leukemia (CML) is a hematopoietic disorder caused by the BCR/ABL gene or Philadelphia chromosome. The first Food and Drug Administration (FDA)-approved tyrosine kinase inhibitor for treatment of CML was imatinib in 2001. Since then, multiple therapies, such as nilotinib, dasatinib, bosutinib, and, more recently, ponatinib, have made their way as viable treatment options for first-line and secondary therapies. Most patients tend to respond to first-line treatment. Although there is a subset of patients who do not achieve complete molecular response with first line, newer options have proven beneficial. As we progress through therapies, there still remain some patients who do not adequately respond to current available therapies. The treatment options and guidelines become more difficult in such situations, not only with respect to cost but also patient quality of life and satisfaction. We discuss a 75-year-old white female with CML, who has had multiple therapies with hematological remission but has never achieved complete molecular remission, currently on bosutinib and tolerating it well.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>32518550</pmid><doi>10.1159/000506895</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1662-6575 |
ispartof | Case reports in oncology, 2020-05, Vol.13 (2), p.534-537 |
issn | 1662-6575 1662-6575 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_c9e85d8d727d45db9753bbe96a56efed |
source | Open Access: PubMed Central; publisher website |
subjects | Biopsy Blood Bone marrow Case Report Case reports chronic myelogenous leukemia complete molecular remission Drug dosages Hematology Inhibitor drugs Kinases Leukemia Literature reviews major molecular response Mutation Patients refractory Remission (Medicine) Targeted cancer therapy tyrosine kinase inhibitors |
title | Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T15%3A11%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20a%2075-Year-Old%20Lady%20with%20Refractory%20Chronic%20Myelogenous%20Leukemia&rft.jtitle=Case%20reports%20in%20oncology&rft.au=Sobash,%20Philip%20T.&rft.date=2020-05-01&rft.volume=13&rft.issue=2&rft.spage=534&rft.epage=537&rft.pages=534-537&rft.issn=1662-6575&rft.eissn=1662-6575&rft_id=info:doi/10.1159/000506895&rft_dat=%3Cproquest_doaj_%3E2447958188%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c529t-f2728f69395d81658c0ea8aa10566dcf2ac2597b28c51561671dec1aec6553ae3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2447958188&rft_id=info:pmid/32518550&rfr_iscdi=true |